Observational Non-Interventional Study Of Febrile Neutropenia Patients To Evaluate Antibacterial Therapeutical Options

NCT00945555

Last updated date
Study Location
Pfizer Investigational Site
Ankara, , 06500, Turkey
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Febrile Neutropenia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients who are 18 years old and above.

- Patients who have undergone allogeneic/autologous or peripheral stem cell transplantation following induction or consolidation treatment due to acute hematological malignancy.

- Patients who have a neutrophil count below 500 cells per cubic millimeter (cells/mm^3) or below 1000 cells/mm^3 with an expectancy to rapidly decrease below 500 cells/mm^3.

- Patients with a body temperature more than or equal to (≥)38.3 degrees Celsius (101 degrees Fahrenheit) on single oral measurement or detected ≥38.0 degrees Celsius for at least an hour and thus started on antibacterial treatment will be included in the trial.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Patients who are pregnant or considering pregnancy.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Febrile NeutropeniaTreatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection
NCT00035425
  1. Los Angeles, California
  2. Springfield, Illinois
  3. Springfield, Illinois
  4. Springfield, Illinois
  5. Springfield, Illinois
  6. Bronx, New York
  7. Bronx, New York
  8. Houston, Texas
  9. Richmond, Virginia
  10. Richmond, Virginia
  11. Richmond, Virginia
  12. Richmond, Virginia
  13. Richmond, Virginia
  14. Federal Way, Washington
  15. Lakewood, Washington
  16. Tacoma, Washington
  17. Buenos Aires,
  18. Cordoba,
  19. Mendoza,
  20. Porto Alegre, RS
  21. Porto Alegre, RS
  22. Sao Paulo, SP
  23. São Paulo, SP
  24. São Paulo,
  25. São Paulo,
  26. Santiago,
  27. Bogota, Bogota. DC
  28. Bogota, Bogota. DC
  29. Medellin,
  30. Helsinki,
  31. Zapopan, Jalisco
  32. Monterrey, Nuevo Leon
  33. Mexico D.f.,
  34. Lahore, Punjab
  35. Karachi,
  36. Lima,
  37. Lima,
  38. Caracas, Distrito Federal
  39. Caracas,
ALL GENDERS
13 Years+
years
MULTIPLE SITES
Febrile NeutropeniaObservational Non-Interventional Study Of Febrile Neutropenia Patients To Evaluate Antibacterial Therapeutical Options
NCT00945555
  1. Ankara,
  2. Bursa,
  3. Istanbul,
  4. Kayseri,
  5. Kocaeli,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Observational Non-Interventional Study Of Febrile Neutropenia Patients To Evaluate Antibacterial Therapeutical Options
Official Title Multi-Center, Non-Interventional, Observational Study To Evaluate The Antibacterial Therapeutical Options In Febrile Neutropenia Patients
Brief Summary The purpose of this study was to define and classify antibacterial agents used in Turkey for patients with febrile neutropenia.
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Patients with febrile neutropenia who were planning to take antibacterial treatment.
Condition Febrile Neutropenia
Intervention Drug: Antibacterial agent for the treatment of febrile neutropenia
The antibacterial agent used by the investigators for febrile neutropenia will be determined and classified in the preference order
Study Groups/Cohorts All participants
Participants with febrile neutropenia who received antibacterial treatment per investigator's judgment
Intervention: Drug: Antibacterial agent for the treatment of febrile neutropenia
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: September 23, 2011)
264
Original Estimated Enrollment
 (submitted: July 23, 2009)
120
Actual Study Completion Date October 2010
Actual Primary Completion Date October 2010   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Patients who are 18 years old and above.
  • Patients who have undergone allogeneic/autologous or peripheral stem cell transplantation following induction or consolidation treatment due to acute hematological malignancy.
  • Patients who have a neutrophil count below 500 cells per cubic millimeter (cells/mm^3) or below 1000 cells/mm^3 with an expectancy to rapidly decrease below 500 cells/mm^3.
  • Patients with a body temperature more than or equal to (?)38.3 degrees Celsius (101 degrees Fahrenheit) on single oral measurement or detected ?38.0 degrees Celsius for at least an hour and thus started on antibacterial treatment will be included in the trial.

Exclusion Criteria:

- Patients who are pregnant or considering pregnancy.

Sex/Gender
Sexes Eligible for Study:All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Turkey
Removed Location Countries  
 
Administrative Information
NCT Number NCT00945555
Other Study ID Numbers A1891006
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date March 2017